Physician profile
Christopher S Wolfe
NPI 1427219617
$154,313.44
in general payments reported to CMS, 2019-2025
24 companies · $30K in 2025
The $30K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,060 · 2020: $17K · 2021: $36K · 2022: $38K · 2023: $5,868 · 2024: $19K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22K · Consulting Fee: $18K · Travel and Lodging: $9,837 · Food and Beverage: $5,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,247.50 |
| Consulting Fee | $18,150.00 |
| Travel and Lodging | $9,836.87 |
| Food and Beverage | $5,472.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $49,461.10 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Cvi Contact Lens |
| Allergan, INC. | $37,870.87 | 2019-2022 | |
| Astellas Pharma US INC | $19,300.89 | 2023-2025 | Izervay |
| Sight Sciences, INC. | $17,153.02 | 2019-2023 | Tearcare System |
| Abbvie INC. | $10,473.49 | 2022-2023 | Vuity |
| Johnson & Johnson Surgical Vision, INC. | $7,172.55 | 2019-2024 | Lipiflow System Activator (Disposable), Lipiview Ocular Surface Interferometer, Meibomian Gland Evaluator |
| Lumenis Be INC | $5,200.00 | 2022 | |
| Optos, INC. | $1,057.43 | 2019-2022 | |
| Lkc Technologies, INC. | $954.58 | 2024-2025 | |
| Carl Zeiss Meditec, INC. | $893.64 | 2022 | |
| Sun Pharmaceutical Industries INC. | $767.04 | 2020-2024 | Cequa |
| Maculogix, INC. | $765.02 | 2019-2020 | |
| Topcon Healthcare, INC. | $741.80 | 2023-2025 | |
| Alcon Vision LLC | $713.39 | 2021-2025 | Total30, Dailies Total1, Precision7 |
| Bausch & Lomb Americas INC. | $607.58 | 2022-2025 | Infuse |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $535.39 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $218.88 | 2019-2022 | |
| Biotissue Holdings INC. | $107.78 | 2022-2025 | |
| Oyster Point Pharma, INC. | $103.13 | 2022 | |
| Organogenesis INC. | $95.67 | 2024 | Affinity |
| Horizon Therapeutics Plc | $61.59 | 2020-2022 | |
| Kala Pharmaceuticals, INC. | $22.71 | 2021 | |
| Shire North American Group INC | $19.88 | 2019 | |
| Immunogen, INC. | $16.01 | 2023 | Elahere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.